Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood

Kenneth G. Frey, Jesus E. Herrera-Galeano, Cassie L. Redden, Truong V. Luu, Stephanie L. Servetas, Alfred J. Mateczun, Vishwesh P. Mokashi, Kimberly A. Bishop-Lilly

Research output: Contribution to journalArticle

Abstract

Background: The introduction of benchtop sequencers has made adoption of whole genome sequencing possible for a broader community of researchers than ever before. Concurrently, metagenomic sequencing (MGS) is rapidly emerging as a tool for interrogating complex samples that defy conventional analyses. In addition, next-generation sequencers are increasingly being used in clinical or related settings, for instance to track outbreaks. However, information regarding the analytical sensitivity or limit of detection (LoD) of benchtop sequencers is currently lacking. Furthermore, the specificity of sequence information at or near the LoD is unknown.Results: In the present study, we assess the ability of three next-generation sequencing platforms to identify a pathogen (viral or bacterial) present in low titers in a clinically relevant sample (blood). Our results indicate that the Roche-454 Titanium platform is capable of detecting Dengue virus at titers as low as 1X102.5 pfu/mL, corresponding to an estimated 5.4X104 genome copies/ml maximum. The increased throughput of the benchtop sequencers, the Ion Torrent PGM and Illumina MiSeq platforms, enabled detection of viral genomes at concentrations as low as 1X104 genome copies/mL. Platform-specific biases were evident in sequence read distributions as well as viral genome coverage. For bacterial samples, only the MiSeq platform was able to provide sequencing reads that could be unambiguously classified as originating from Bacillus anthracis.Conclusion: The analytical sensitivity of all three platforms approaches that of standard qPCR assays. Although all platforms were able to detect pathogens at the levels tested, there were several noteworthy differences. The Roche-454 Titanium platform produced consistently longer reads, even when compared with the latest chemistry updates for the PGM platform. The MiSeq platform produced consistently greater depth and breadth of coverage, while the Ion Torrent was unequaled for speed of sequencing. None of the platforms were able to verify a single nucleotide polymorphism responsible for antiviral resistance in an Influenza A strain isolated from the 2009 H1N1 pandemic. Overall, the benchtop platforms perform well for identification of pathogens from a representative clinical sample. However, unlike identification, characterization of pathogens is likely to require higher titers, multiple libraries and/or multiple sequencing runs.

Original languageEnglish (US)
Article number96
JournalBMC Genomics
Volume15
Issue number1
DOIs
StatePublished - Feb 4 2014
Externally publishedYes

Fingerprint

Metagenomics
Viral Genome
Genome
Titanium
Limit of Detection
Ions
Bacillus anthracis
Dengue Virus
Pandemics
Viral Load
Human Influenza
Libraries
Antiviral Agents
Single Nucleotide Polymorphism
Disease Outbreaks
Research Personnel

ASJC Scopus subject areas

  • Biotechnology
  • Genetics

Cite this

Frey, K. G., Herrera-Galeano, J. E., Redden, C. L., Luu, T. V., Servetas, S. L., Mateczun, A. J., ... Bishop-Lilly, K. A. (2014). Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood. BMC Genomics, 15(1), [96]. https://doi.org/10.1186/1471-2164-15-96

Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood. / Frey, Kenneth G.; Herrera-Galeano, Jesus E.; Redden, Cassie L.; Luu, Truong V.; Servetas, Stephanie L.; Mateczun, Alfred J.; Mokashi, Vishwesh P.; Bishop-Lilly, Kimberly A.

In: BMC Genomics, Vol. 15, No. 1, 96, 04.02.2014.

Research output: Contribution to journalArticle

Frey, KG, Herrera-Galeano, JE, Redden, CL, Luu, TV, Servetas, SL, Mateczun, AJ, Mokashi, VP & Bishop-Lilly, KA 2014, 'Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood', BMC Genomics, vol. 15, no. 1, 96. https://doi.org/10.1186/1471-2164-15-96
Frey, Kenneth G. ; Herrera-Galeano, Jesus E. ; Redden, Cassie L. ; Luu, Truong V. ; Servetas, Stephanie L. ; Mateczun, Alfred J. ; Mokashi, Vishwesh P. ; Bishop-Lilly, Kimberly A. / Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood. In: BMC Genomics. 2014 ; Vol. 15, No. 1.
@article{6ff9d40d7f7a42b9bd4e8b7532a43dd2,
title = "Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood",
abstract = "Background: The introduction of benchtop sequencers has made adoption of whole genome sequencing possible for a broader community of researchers than ever before. Concurrently, metagenomic sequencing (MGS) is rapidly emerging as a tool for interrogating complex samples that defy conventional analyses. In addition, next-generation sequencers are increasingly being used in clinical or related settings, for instance to track outbreaks. However, information regarding the analytical sensitivity or limit of detection (LoD) of benchtop sequencers is currently lacking. Furthermore, the specificity of sequence information at or near the LoD is unknown.Results: In the present study, we assess the ability of three next-generation sequencing platforms to identify a pathogen (viral or bacterial) present in low titers in a clinically relevant sample (blood). Our results indicate that the Roche-454 Titanium platform is capable of detecting Dengue virus at titers as low as 1X102.5 pfu/mL, corresponding to an estimated 5.4X104 genome copies/ml maximum. The increased throughput of the benchtop sequencers, the Ion Torrent PGM and Illumina MiSeq platforms, enabled detection of viral genomes at concentrations as low as 1X104 genome copies/mL. Platform-specific biases were evident in sequence read distributions as well as viral genome coverage. For bacterial samples, only the MiSeq platform was able to provide sequencing reads that could be unambiguously classified as originating from Bacillus anthracis.Conclusion: The analytical sensitivity of all three platforms approaches that of standard qPCR assays. Although all platforms were able to detect pathogens at the levels tested, there were several noteworthy differences. The Roche-454 Titanium platform produced consistently longer reads, even when compared with the latest chemistry updates for the PGM platform. The MiSeq platform produced consistently greater depth and breadth of coverage, while the Ion Torrent was unequaled for speed of sequencing. None of the platforms were able to verify a single nucleotide polymorphism responsible for antiviral resistance in an Influenza A strain isolated from the 2009 H1N1 pandemic. Overall, the benchtop platforms perform well for identification of pathogens from a representative clinical sample. However, unlike identification, characterization of pathogens is likely to require higher titers, multiple libraries and/or multiple sequencing runs.",
author = "Frey, {Kenneth G.} and Herrera-Galeano, {Jesus E.} and Redden, {Cassie L.} and Luu, {Truong V.} and Servetas, {Stephanie L.} and Mateczun, {Alfred J.} and Mokashi, {Vishwesh P.} and Bishop-Lilly, {Kimberly A.}",
year = "2014",
month = "2",
day = "4",
doi = "10.1186/1471-2164-15-96",
language = "English (US)",
volume = "15",
journal = "BMC Genomics",
issn = "1471-2164",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Comparison of three next-generation sequencing platforms for metagenomic sequencing and identification of pathogens in blood

AU - Frey, Kenneth G.

AU - Herrera-Galeano, Jesus E.

AU - Redden, Cassie L.

AU - Luu, Truong V.

AU - Servetas, Stephanie L.

AU - Mateczun, Alfred J.

AU - Mokashi, Vishwesh P.

AU - Bishop-Lilly, Kimberly A.

PY - 2014/2/4

Y1 - 2014/2/4

N2 - Background: The introduction of benchtop sequencers has made adoption of whole genome sequencing possible for a broader community of researchers than ever before. Concurrently, metagenomic sequencing (MGS) is rapidly emerging as a tool for interrogating complex samples that defy conventional analyses. In addition, next-generation sequencers are increasingly being used in clinical or related settings, for instance to track outbreaks. However, information regarding the analytical sensitivity or limit of detection (LoD) of benchtop sequencers is currently lacking. Furthermore, the specificity of sequence information at or near the LoD is unknown.Results: In the present study, we assess the ability of three next-generation sequencing platforms to identify a pathogen (viral or bacterial) present in low titers in a clinically relevant sample (blood). Our results indicate that the Roche-454 Titanium platform is capable of detecting Dengue virus at titers as low as 1X102.5 pfu/mL, corresponding to an estimated 5.4X104 genome copies/ml maximum. The increased throughput of the benchtop sequencers, the Ion Torrent PGM and Illumina MiSeq platforms, enabled detection of viral genomes at concentrations as low as 1X104 genome copies/mL. Platform-specific biases were evident in sequence read distributions as well as viral genome coverage. For bacterial samples, only the MiSeq platform was able to provide sequencing reads that could be unambiguously classified as originating from Bacillus anthracis.Conclusion: The analytical sensitivity of all three platforms approaches that of standard qPCR assays. Although all platforms were able to detect pathogens at the levels tested, there were several noteworthy differences. The Roche-454 Titanium platform produced consistently longer reads, even when compared with the latest chemistry updates for the PGM platform. The MiSeq platform produced consistently greater depth and breadth of coverage, while the Ion Torrent was unequaled for speed of sequencing. None of the platforms were able to verify a single nucleotide polymorphism responsible for antiviral resistance in an Influenza A strain isolated from the 2009 H1N1 pandemic. Overall, the benchtop platforms perform well for identification of pathogens from a representative clinical sample. However, unlike identification, characterization of pathogens is likely to require higher titers, multiple libraries and/or multiple sequencing runs.

AB - Background: The introduction of benchtop sequencers has made adoption of whole genome sequencing possible for a broader community of researchers than ever before. Concurrently, metagenomic sequencing (MGS) is rapidly emerging as a tool for interrogating complex samples that defy conventional analyses. In addition, next-generation sequencers are increasingly being used in clinical or related settings, for instance to track outbreaks. However, information regarding the analytical sensitivity or limit of detection (LoD) of benchtop sequencers is currently lacking. Furthermore, the specificity of sequence information at or near the LoD is unknown.Results: In the present study, we assess the ability of three next-generation sequencing platforms to identify a pathogen (viral or bacterial) present in low titers in a clinically relevant sample (blood). Our results indicate that the Roche-454 Titanium platform is capable of detecting Dengue virus at titers as low as 1X102.5 pfu/mL, corresponding to an estimated 5.4X104 genome copies/ml maximum. The increased throughput of the benchtop sequencers, the Ion Torrent PGM and Illumina MiSeq platforms, enabled detection of viral genomes at concentrations as low as 1X104 genome copies/mL. Platform-specific biases were evident in sequence read distributions as well as viral genome coverage. For bacterial samples, only the MiSeq platform was able to provide sequencing reads that could be unambiguously classified as originating from Bacillus anthracis.Conclusion: The analytical sensitivity of all three platforms approaches that of standard qPCR assays. Although all platforms were able to detect pathogens at the levels tested, there were several noteworthy differences. The Roche-454 Titanium platform produced consistently longer reads, even when compared with the latest chemistry updates for the PGM platform. The MiSeq platform produced consistently greater depth and breadth of coverage, while the Ion Torrent was unequaled for speed of sequencing. None of the platforms were able to verify a single nucleotide polymorphism responsible for antiviral resistance in an Influenza A strain isolated from the 2009 H1N1 pandemic. Overall, the benchtop platforms perform well for identification of pathogens from a representative clinical sample. However, unlike identification, characterization of pathogens is likely to require higher titers, multiple libraries and/or multiple sequencing runs.

UR - http://www.scopus.com/inward/record.url?scp=84893206783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893206783&partnerID=8YFLogxK

U2 - 10.1186/1471-2164-15-96

DO - 10.1186/1471-2164-15-96

M3 - Article

C2 - 24495417

AN - SCOPUS:84893206783

VL - 15

JO - BMC Genomics

JF - BMC Genomics

SN - 1471-2164

IS - 1

M1 - 96

ER -